CTLA4 and hepatocellular carcinoma: Similarly, the CheckMate 040 trial aimed to assess different dosing plans of nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) in HCC patients that had received sorafenib treatment and reported the highest ORR in the treatment arm that received nivolumab plus a higher dose of ipilimumab (4 doses/every 3 weeks) followed by nivolumab every 2 weeks [29].